A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC

Non-small Cell Lung Cancer Clinical Trial

Official title:

Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Advanced or Metastatic Non-small Cell Lung Cancer Patients : a Phase II, Historical Control, Biomarker-selected Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04612673
• Other study ID #: CIBI308Y035
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: November 20, 2020
• Est. completion date: December 31, 2022

Study information

• Verified date: October 2020
• Source: China Medical University, China
• Contact: Shuo Wang, PhD
• Phone: 0086-024-83281806
• Email: suresure_wang[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to to explore the efficacy and safety of PD-1 immune check point inhibitor, sintilimab, in biomarker-selected subjects with advanced or metastatic Non-small Cell Lung Cancer who have failed from standard front-line treatment.

Description:

This study is planned to be carried out in The First Hospital of China Medical University. 33 cases are preliminarily expected to be included. The study started in October 2020 and ended in October 2023. It is expected that the trial will end in October 2023.

In the absence of such situations as withdrawal of informed consent, intolerance of drug toxicity and side effects, or inappropriateness for further trials, each participant's expected time for research and treatment will continue until radiographically confirmed tumor progression occurs.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 33
• Est. completion date: December 31, 2022
• Est. primary completion date: June 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• = 18 and = 70 years of age , regardless of gender;

• Pathologically confirmed diagnosis of locally advanced or metastatic NSCLC (according to the eighth edition of AJCC staging, IIIB, IIIC, IV), with at least one measurable lesion (RECIST 1.1)

• treatment failure after first-line standard treatment (definition of treatment failure: intolerable side effects, disease progression during or after treatment);

• No known EGFR sensitive mutations and ALK gene rearrangements.

• Tumor tissue samples that meet the testing requirements for biomarker testing can be provided. Testing will be carried out in the central laboratory.

• NSCLC that is anti-programmed cell death ligand 1 (PD-L1) positive(TPS PD-L1 expression is =1% ), and CD8 expression is =20% (pre-treatment samples are sufficient).

• ECOG PS: 0-1

• Sufficient organ and bone marrow function as defined below:

1. Routine blood examination:

1. HB=90g/L;

2. ANC =1.5×109/L;

3. PLT =90×109/L;

2. Biochemical inspection shall:

1. Total bilirubin = 1.5 ULN;

2. ALT and AST=2.5ULN;

3. Serum Cr=1ULN, endogenous creatinine clearance rate>60ml/min (Cockcroft-Gault);

• The international normalized ratio (INR) = 1.5 and partial prothrombin time (PPT or APTT) = 1.5 ULN within the 7 days before enrollment.

• Life span expectation over 3 months;

• Provide written informed consent;

Exclusion Criteria:

• Allergic to any ingredients of Sintilimab preparations; or have had severe allergic reactions to other monoclonal antibodies in the past.

• Received more than one regimen for the treatment of locally advanced or metastatic NSCLC in the past (except for adjuvant/neoadjuvant chemotherapy that has exceeded the 24-week).

• Received any anti-PD-1/PD-L1 antibody, anti-CTLA4 antibody, or other immunotherapy in the past.

• Diagnosed other malignant tumors within 5 years before the first administration, excluding radically cured skin basal cell carcinoma, skin squamous cell carcinoma and/or radically excised carcinoma in situ.

• Be treated with anti-tumor vaccines or other immunostimulatory anti-tumor drugs (interferon, interleukin, thymosin, immune cell therapy, etc.) within 1 month before enrolled.

• Central nervous system metastasis with symptoms..

• Acute or chronic active hepatitis B (defined as positive for hepatitis B virus surface antigen HBsAg during the screening period) or hepatitis C infection.

• History of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-related pneumonia, severely impaired lung function and other lung diseases.

• Active tuberculosis (TB), who are receiving anti-tuberculosis treatment or have received anti-tuberculosis treatment within 1 year before the first administration.

• People infected with human immunodeficiency virus (HIV) (HIV antibody positive), people with known syphilis infection.

• Patients who are considered to be at greater medical risk due to severe, uncontrollable diseases, non-metastatic systemic diseases, or active, uncontrollable infections.

• An active autoimmune disease that requires systemic treatment (such as the use

• disease-relieving drugs, corticosteroids, or immunosuppressive agents) occurred within 2 years before the first administration.

• Have used immunosuppressive drugs within 4 weeks before the first administration, excluding nasal spray, inhaled or other local glucocorticoids or physiological doses of systemic glucocorticoids (ie not more than 10 mg/day prednisone Loose or equivalent doses of other glucocorticoids), allowing temporary use of glucocorticoids for the treatment of asthma, chronic obstructive pulmonary disease and other diseases such as dyspnea symptoms.

• Exclude subjects who are expected to require any other form of anti-tumor therapy (including maintenance therapy with other NSCLC drugs, radiotherapy, and/or surgical resection) in the study.

• Exclude those who underwent major surgery within 4 weeks before the first medication, those with non-thoracic radiation therapy >30 Gy within 4 weeks before the first medication, those with chest radiation >30 Gy within 24 weeks before the first medication, and 2 before the first medication Subjects who received palliative radiation <30 Gy within a week and who failed to recover from the toxicity and/or complications of these interventions to NCI-CTC AE = 1 degree (except for hair loss and fatigue). Palliative radiotherapy for symptom control is permitted and must be completed at least 2 weeks before the start of treatment with the study drug, and there are no plans for additional radiotherapy to the same lesion. For patients who received radiotherapy 2 weeks before the first administration, all of the following conditions must be met before they can be enrolled: There is no radiotherapy-related toxic reaction, glucocorticoids are not required, and radiation pneumonitis, radiation hepatitis, radioactivity are excluded Enteritis and so on.

• Pregnancy or lactation.

• Participated in other drug clinical trials within four weeks.

• The investigator believes that there are any conditions that may damage the subject or result in the subject not being able to meet or perform the research request.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer

Intervention

Drug:
• Sintilimab
immune checkpoint inhibitor, 200mg, iv, d1,Q3W

Locations

Country	Name	City	State
China	The First Affiliated Hospital of China Medical University	Shenyang	Liaoning

Sponsors (9)

Lead Sponsor	Collaborator
China Medical University, China	Anshan Tumor Hospital, Benxi Cental Hospital, Liaoning Cancer Hospital & Institute, Shengjing Hospital, The First Affiliated Hospital of Dalian Medical University, The First People's Hospital of Jingzhou, The People's Hospital of Liaoning Province, The Second Affiliated Hospital of Dalian Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progress free survival (PFS)	PFS defined as the time from first dose of study treatment until the first date of either objective disease progression or death due to any cause.	untill Progressive Disease(PD) or death(up to 24 months)
Secondary	Overall Survival (OS)	OS is defined as the time until death due to any cause.	From randomization until death (up to 24 months)
Secondary	Objective Response Rate (ORR)	ORR is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1.prior to progression or any further therapy.	each 42 days up to intolerance the toxicity or PD (up to 24 months)
Secondary	Disease Control Rate (DCR)	Defined as the proportion of patients with a documented complete response, partial response, and stable disease (CR + PR + SD) based on RECIST 1.1.	each 42 days up to intolerance the toxicity or PD (up to 24 months)